Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: Our purpose was to describe our initial institutional experience using dedicated brain [18F]-Fluoroestradiol (FES) PET/CT or PET/MRI in the management of patients with estrogen-receptor-positive (ER+) breast cancer brain metastases (BCBM), and compare to [18F]-Fluorodeoxyglucose (FDG) PET and MRI.
Materials & Methods: Patients with biopsy-proven ER+ disease and MRI findings of suspected new, progressive, or recurrent BCBM were included in this retrospective study. Clinical and demographic data were collected. Dedicated brain FES PET/CT or PET/MRI was performed for clinical purposes. Maximum standardized uptake value (SUV) in MRI-defined target lesions and SUV ratio (SUVR, referencing normal-appearing parenchyma) were obtained. Pathology and/or clinical and MRI follow-up data were used as gold standard to classify viable neoplasm versus post-radiotherapy (RT) sequelae. Mann-Whitney tests were performed to compare subgroups.
Results: Seven patients met inclusion criteria. 15/16 (94 %) lesions classified as neoplasm were FES-positive. 4/4 (100 %) lesions classified as RT sequelae were FES-negative. Median tumor FES-SUVR were higher than median RT-sequelae FES-SUVR (6.0 (2.8-9.1) versus 0.5 (0.3-0.7), p < 0.01), and similarly, median tumor FES-SUV were higher than median RT-sequelae FES-SUV (4.8 (2.8-9.1) versus 0.6 (0.3-0.8), p < 0.01). Lesion-based analysis of FDG-SUV and -SUVR demonstrated a trend for higher FDG avidity in lesions characterized as neoplasm; however, this did not reach statistical significance.
Conclusion: Dedicated FES brain PET represents a promising adjunct modality, noting limitations of small sample size, retrospective nature of our study, and the possibility of ER expression heterogeneity. Our findings merit future prospective clinical trials incorporating dedicated brain FES PET/CT and PET/MRI in the management of patients with ER-positive disease and BCBM.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejrad.2024.111791 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Benign Enchondroma in a 40-Year-Old Female: Emphasizing the Importance of Early 18F-FES PET/CT Utilization.
Case Rep Radiol
August 2025
Independent Researcher, Ellicott City, Maryland, USA.
A 40-year-old female with estrogen receptor-positive breast cancer underwent an initial staging using a technetium-99m methylene diphosphonate (Tc-99m MDP) bone scan, which revealed abnormal uptake in the femur without a patient history of prior trauma or associated symptoms. Subsequently, an MRI confirmed the presence of a well-defined lesion in the upper left femur. To rule out metastatic disease, an 18F-fluoroestradiol (FES) PET/CT was performed, demonstrating no ER expression.
View Article and Find Full Text PDFQuantitative and simplified [18F] fluoroestradiol positron emission tomography (PET) measures of brain estrogen receptor expression.
Eur J Nucl Med Mol Imaging
August 2025
Department of Neurology, Weill Cornell Medicine, New York, NY, USA.
Purpose: Positron emission tomography (PET) with 16α-[F]fluoro-17β-estradiol (F-FES) allows for the in vivo assessment of brain estrogen receptor (ER) expression. This study examines brain F-FES uptake to define an optimal acquisition time for static late images suitable for clinical application.
Methods: Fifty-five healthy, 40-65-year-old women at different endocrine aging stages (n = 18 premenopause, n = 18 perimenopause, and n = 19 postmenopause) underwent dynamic 90-minute F-FES PET imaging.
A case of invasive lobular carcinoma, highlighting the emerging role of F-Fluoroestradiol PET.
Radiol Case Rep
October 2025
Department of Radiology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA.
Invasive lobular carcinoma (ILC) presents significant diagnostic challenges due to its subtle presentation on mammography. Its low metabolic activity further limits the detection of metastatic lesions using fluorine-18 (F)-fluorodeoxyglucose-positron emission tomography (FDG-PET). In contrast, F-fluoroestradiol-PET (FES-PET), which targets functional estrogen receptor (ER) expression, enhances visualization of ER-positive metastases.
View Article and Find Full Text PDFF-fluoroestradiol (F-FES) PET/CT for guiding first-line treatment in patients with HR + /HER2- metastatic breast cancer: impact on progression free survival.
Eur J Nucl Med Mol Imaging
July 2025
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Background: While CDK4/6 inhibitors combined with endocrine therapy (CDK4/6i+ET) have revolutionized treatment for HR+/HER2- metastatic breast cancer (MBC), inter-lesional estrogen receptor (ER) heterogeneity limits therapeutic efficacy in a subset of patients. Whole-body F-fluoroestradiol (F-FES) PET/CT enables non-invasive ER quantification across all metastatic sites. However, whether F-FES-guided therapy selection improves clinical outcomes in relatively large sample cohorts is not yet well-established.
View Article and Find Full Text PDFCollagen Vascular Disease-Associated Interstitial Pneumonia With Accumulation of 18F-fluoroestradiol.
Clin Nucl Med
May 2025
Department of Diagnostic Imaging and Nuclear Medicine.
18F-fluoroestradiol (18F-FES) is a PET radiotracer that binds to the estrogen receptor (ER) in the nucleus of ER-expressing cells and is increasingly used clinically in breast cancer patients to visualize ER expression in lesions. Although 18F-FES accumulation is generally specific, radiation-induced pneumonitis can produce false-positive results, but the underlying mechanisms remain largely unclear. Here, we report the case of a 72-year-old woman with known collagen vascular disease-associated interstitial pneumonia and the accumulation of 18F-FES on 18F-FES-PET/CT, which was conducted to investigate suspected recurrent breast cancer.
View Article and Find Full Text PDF